Previous 10 | Next 10 |
home / stock / rhhby / rhhby news
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . The crisis at Boeing is deepening after the planemaker halted production of a 737 line for the first time in two decades, as the ...
The FTC closes its probe into Roche's ( OTCQX:RHHBY ) $4.8B acquisition of Spark Therapeutics (NASDAQ: ONCE ). More news on: Roche Holding AG, Spark Therapeutics, Inc., Healthcare stocks news, Top stock market news Read more ...
- Zika virus infection is linked to brain defects in fetuses and newborn infants as well as neurological complications in children and adults - Asymptomatic Zika virus infection in blood donors can pose a risk to the blood supply - cobas Zika test expands Roche's industr...
The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending approval of Eli Lilly's (NYSE: LLY ) Cyramza (ramucirumab), combined with Roche ( OTCQX:RHHBY ) and Astellas Pharma's ( OTCPK:ALPMF ) Tarceva (erlotinib), for the first-line treatment of adult p...
Exelixis (NASDAQ: EXEL ) announces positive results from IMspire150, the Phase 3 trial of atezolizumab (TECENTRIQ), cobimetinib (COTELLIC) and vemurafenib (ZELBORAF) in people with previously untreated BRAF V600 mutation-positive advanced melanoma. More news on: Exelixis, Inc., Roche Hol...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS). The study showed adding Tecentri...
Of all the new science coming in through ASH 2019, one of the most important abstracts is this one from Roche (RHHBY). Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Recept...
By a 230-192 margin, the U.S. House of Representatives has passed legislation , championed by Speaker Nancy Pelosi, aimed at corralling spiralling drug costs. More news on: ProShares Trust - ProShares Ultra Nasdaq Biotechnology, Tekla World Healthcare Fund, ARK Genomic Revolution Multi-Se...
AstraZeneca (NYSE: AZN) recently impressed a crowd of oncologists at the annual San Antonio Breast Cancer Symposium with surprisingly good clinical trial results. In a nutshell, it looks like an experimental drug that the company licensed from Daiichi Sankyo (OTC: DSNKY) c...
INDIANAPOLIS , Dec. 12, 2019 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has signed a joint marketing agreement in the United States with Fortelinea Software Systems that allows for the linking of Roche's VENTANA Connect middleware with Fortelinea's Pri...
News, Short Squeeze, Breakout and More Instantly...
Roche Holding Ltd ADR Company Name:
RHHBY Stock Symbol:
OTCMKTS Market:
The obesity market has garnered much interest lately, ever since Novo Nordisk (NYSE: NVO) received FDA approval for its obesity drug Wegovy in 2021...
Thursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP r...
– Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant mean placebo-adjusted weight loss of 18.8% (p < 0.001) – – At week 24, 100% of CT-388 treated participants achieved >5% weight loss, 70...